1279691-36-9 Usage
Description
(2S,3R,4S,5S,6R)-2-(3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)-4-chlorophenyl)-tetrahydro-6-(hydroxyMethyl)-2-Methoxy-2H-pyran-3,4,5-triol is a complex organic compound with a unique molecular structure. It is characterized by its stereochemistry, with five chiral centers (2S, 3R, 4S, 5S, 6R), and a tetrahydrofuran-3-yloxy group attached to a benzyl moiety. The compound also features a 4-chlorophenyl group and a hydroxymethyl group, as well as a methoxy group. Its specific structure and functional groups may confer potential applications in various fields.
Uses
1. Pharmaceutical Industry:
(2S,3R,4S,5S,6R)-2-(3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)-4-chlorophenyl)-tetrahydro-6-(hydroxyMethyl)-2-Methoxy-2H-pyran-3,4,5-triol is used as a potential pharmaceutical candidate for the development of new drugs. Its unique structure and functional groups may allow it to interact with specific biological targets, potentially leading to the development of novel therapeutics.
2. Chemical Research:
In the field of chemical research, this compound can be used as a starting material or intermediate for the synthesis of other complex organic molecules. Its unique structure and functional groups may enable the development of new synthetic routes and methodologies.
3. Impurity in Drug Synthesis:
As an impurity in the synthesis of Empagliflozin (E521510), a potent and selective inhibitor of sodium glucose co-transporter-2 (SGLT-2), this compound may be relevant in the pharmaceutical industry. Understanding and controlling the presence of such impurities is crucial for ensuring the safety, efficacy, and quality of the final drug product.
4. Drug Delivery Systems:
Similar to gallotannin, this compound may have potential applications in drug delivery systems. Its unique structure and functional groups could be exploited to develop novel drug carriers, potentially improving the delivery, bioavailability, and therapeutic outcomes of various drugs.
Please note that the specific applications and uses of (2S,3R,4S,5S,6R)-2-(3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)-4-chlorophenyl)-tetrahydro-6-(hydroxyMethyl)-2-Methoxy-2H-pyran-3,4,5-triol may vary depending on its properties, which are not fully detailed in the provided materials. Further research and experimentation would be necessary to determine its exact potential and applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1279691-36-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,7,9,6,9 and 1 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1279691-36:
(9*1)+(8*2)+(7*7)+(6*9)+(5*6)+(4*9)+(3*1)+(2*3)+(1*6)=209
209 % 10 = 9
So 1279691-36-9 is a valid CAS Registry Number.
1279691-36-9Relevant articles and documents
Synthesis, Isolation, Characterization and Suppression of Impurities during Optimization of Empagliflozin (Jardiance)
Liu, Xiao,Peng, Peng,Yang, Jiangtao,Yu, Jun,Zhang, Fuli,Zhao, Chuanmeng
, (2022/03/14)
-
Method for preparing intermediates of gliflozin hypoglycemic drugs
-
Paragraph 0055; 0058, (2020/05/02)
The invention belongs to the technical field of medicine synthesis, and relates to a novel method for preparing key intermediates of gliflozin hypoglycemic drugs, in particular to a preparation methodof key intermediates (C-1, D-1 and E-1) of canagliflozin, dapagliflozin and empagliflozin. The method comprises the following steps: 1) in the presence of a cosolvent, carrying out halogen metal exchange on a raw material, namely aryl bromide 2 and an organic lithium reagent to obtain an aryl lithium reagent 3, and carrying out a nucleophilic addition reaction on the aryl lithium reagent 3 and TMS-protected glucolactone 4 to obtain a transition product 5; and 2) removing a TMS protecting group from the transition product 5, and converting hemiketal into ketal to obtain the key intermediate 1with a single configuration. According to the method, the key intermediates (C-1, D-1 and E-1) of canagliflozin, dapagliflozin and empagliflozin can be stereoselectively synthesized, reaction yield isrelatively high (more than 75%), and product purity is high (wherein HPLC purity is about 95%); so reduction preparation of a final product in the next step is facilitated.
Preparation method suitable for industrial production of empagliflozin
-
, (2019/08/12)
The invention belongs to the technical field of organic synthesis route design and medicine and chemical engineering, particularly relates to a synthesis method of a sodium-glucose cotransporter 2(SGLT2) inhibitor, and more particularly relates to a preparation method of empagliflozin. The empagliflozin is synthesized by taking (3S)-3-[4-[(2-chloro-5-iodophenyl) methyl] phenoxy] tetrahydrofuran and glucono delta-lactone as initial raw materials through a series of substep reactions such as protection, addition, substitution, deprotection and reduction. In the synthesis steps disclosed by the invention, a staged target product does not need to be separated and purified after each step of reaction, and the target product is finally obtained by directly subjecting a high-purity reaction intermediate to subsequent steps. The preparation method is simple in process, simple and convenient to operate and good in industrial prospect.